Clinical trials: Androgen Deprivation Therapy
Prostate Cancer
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects…
- Trial name
- NCT07335796
- Testing
- BMS-986165, Degarelix
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01120262
- Testing
- gene expression analysis, polymorphism analysis, laboratory biomarker analysis
- Volunteers
- 545 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer Metastatic
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The aim of the study is to assess the clinical utility of 18F-fluoro-deoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT) and Whole Body Magnetic Resonance Imaging (MRI) versus conventional bone scan and…
- Trial name
- NCT02814968
- Testing
- Enzalutamide, 18-FDG PET/CT, Whole body MRI
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- The European Uro-Oncology Group
Prostate Cancer Metastatic Disease
Role of Race in Nutritional Approach in Men on ADT
There is a well-documented association between androgen deprivation therapy (ADT) and cardiovascular morbidity. A majority of men on ADT gain weight contributing to an increase in cardiovascular risk factors (CVRFs) and…
- Trial name
- NCT06682390
- Testing
- Hypocaloric anti-inflammatory diet
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, Los Angeles
Prostate Cancer, Malignant Neoplasm of Prostate
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment.
- Conditions
- Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
- Trial name
- NCT06150417
- Testing
- Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration…
- Trial name
- NCT02918968
- Testing
- Enzalutamide, Flutamide, Androgen deprivation therapy
- Where
- 47 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Astellas Pharma Inc
Prostate Adenocarcinoma, Stage IIA Prostate Cancer
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
This randomized phase II trial studies the side effects and how well giving leuprolide acetate or goserelin acetate works compared to observation in treating patients with high-risk prostate cancer who have undergone radical…
- Conditions
- Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT00937768
- Testing
- Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Rising Prostate Specific Antigen (PSA)
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer
- Trial name
- NCT02796898
- Testing
- SM88 (Cohort 1), SM88 (Cohort 2)
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Tyme, Inc
Prostate Cancer
Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.
Prostate cancer biochemical recurrence (BCR) occurs in 20-50% of patients following radical prostatectomy or radiotherapy. Due to significant risk of side effects and uncertainty about the benefits, physicians and patients are…
- Trial name
- RCT-EPAII-BCR (NCT03753334)
- Testing
- MAG-EPA
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- CHU de Quebec-Universite Laval
Non-metastatic, Hormone naïve Prostate Cancer
EXTEND Exercise Trial
This study will examine the effect of supervised exercise training on cardiopulmonary function in men receiving the combination of enzalutamide (ENZ) and androgen deprivation therapy (ADT) for treatment of non-metastatic…
- Trial name
- NCT02256111
- Testing
- Enzalutamide, Androgen deprivation therapy, Supervised exercise training
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Duke University
Prostate Cancer Adenocarcinoma in Situ
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to…
- Trial name
- NCT01696877
- Testing
- degarelix acetate, Cyclophosphamide, GVAX
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer.
- Trial name
- NCT06130995
- Testing
- Relugolix and Enzalutamide
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Oklahoma
Prostate Cancer
Stellate Ganglion Block for Hot Flushes in Men Treated With ADT
Androgen deprivation therapy (ADT) is widely used as standard therapy in the treatment of locally advanced and metastatic prostate cancer. Hot flushes and night sweats are one of the main side-effects of ADT.
- Trial name
- NCT02295163
- Testing
- Stellate ganglion block
- Where
- Netherlands
- Sponsor
- Rijnstate Hospital
Oligometastatic Prostate Cancer (OMPC)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary…
- Trial name
- PSMA-DC (NCT05939414)
- Testing
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Metabolic Syndrome
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
This is a multi-centre, double-blind, randomized phase III trial comparing metformin to placebo in patients with advanced prostate cancer starting (or have recently started) androgen deprivation therapy (ADT).
- Trial name
- PRIME (NCT03031821)
- Testing
- Metformin
- Where
- 16 sites in Canada
- Volunteers
- 166 people
- Sponsor
- Canadian Urologic Oncology Group
Prostate Cancer, Bone Metastases
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Trial name
- NCT02582749
- Testing
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Ajjai Alva, MD
Prostate Adenocarcinoma
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
This phase 2 trial studies radium Ra 223 dichloride, hormone therapy and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body.
- Trial name
- NCT03361735
- Testing
- Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer, Salvage Radiotherapy
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
The optimal indication for ADT has long been a point of controversy, at least until the results of randomised trials comparing RT with and without ADT were published.
- Conditions
- Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy
- Trial name
- URONCOR 06-24 (NCT05781217)
- Testing
- triptorelin, goserelin, leuprorelin
- Where
- 17 sites in Spain
- Volunteers
- 534 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer
Comparison of Duration of Treatment Interruption With or Without Curcumin During the Off Treatment Periods in Patients With Prostate Cancer Undergoing Intermittent Androgen Deprivation Therapy
This was a placebo-controlled, double-blind, randomized trial designed with the aim of establishing whether curcumin influenced the duration of treatment interruption and rate of prostatic specific antigen(PSA) progression…
- Trial name
- NCT03211104
- Testing
- curcumin
- Volunteers
- 107 people
- Sponsor
- Samsung Medical Center